A Non Interventional Study To Asses The Safety, Effectiveness And Tolerability Of Quinapril (Acupil®) In An Indian Population (ASSET)

Pfizer

Status: Completed

Conditions: Hypertension

Treatments: Drug: quinapril

Study type: Observational

Funder types: Industry

Identifiers

NCT00930722

A9061066

Details and patient eligibility

About

This is a prospective, non-interventional, non comparative drug study. The efficacy of Quinapril in Asian population has been evaluated, but specifically in Indian patients the data is sparse. Data in a real world setting in a large population of Indian patients would shed more light on the safety, tolerability and effectiveness of Quinapril in the Indian population.

Enrollment: 329 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients already on therapy with Acupil® for a minimum period of 4 weeks, Evidence of a personally signed and dated informed consent document

Exclusion criteria

• Patients having a Week 0 visit blood pressure reading of more than 180/110 mm of Hg will not be eligible to participate in the study.
• Women of child bearing age, not willing to use contraceptives, will not be eligible for the study
• Women using oral contraceptives will also not be included in the study
• Patients who have received any drug other than Acupil® as the first prescribed antihypertensive would not be eligible for enrollment into the trial
• Patients having any complication at Week 0 visit which would require more thorough investigations or who required more than one anti-hypertensive drug at the time of initiation of their therapy will not be included in the study
• Patients having any contraindications as per the LPD of Acupil®

Trial design

329 participants in 1 patient group

quinapril

Description:

quinapril

Treatment:

Drug: quinapril